Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma
- PMID: 17308358
- DOI: 10.1385/ep:17:3:213
Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma
Abstract
The accurate diagnosis of differentiated thyroid tumors is very important for clinical management of patients. The histopathological distinction between some types of differentiated thyroid tumors can be very difficult even for experienced pathologists. We used immunohistochemical markers from published data obtained from DNA expression profiling, tissue microarray analysis, and immunohistochemistry to analyze a series of 157 thyroid tumors and 5 normal thyroids. These analyses showed that several antibodies were useful in distinguishing follicular adenomas from follicular variant of papillary thyroid carcinomas including HBME-1, CITED1, galectin-3, cytokeratin 19, and S100A4 (p < 0.0001). A combination of markers consisting of a panel of HBME-1, galectin-3, and CK19 or a panel of HBME-1, CITED1, and galectin-3 was usually most effective in distinguishing follicular adenoma from follicular variant of papillary thyroid carcinoma. Because individual tumors may not express some of these markers, the use of a panel of antibodies is recommended. These results indicate that some individual antibodies or a panel of antibodies combined with histopathological analysis can be useful in separating follicular adenoma (FA) from follicular variant of papillary thyroid carcinoma (FVPTC).
Similar articles
-
Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.APMIS. 2012 May;120(5):368-79. doi: 10.1111/j.1600-0463.2011.02842.x. Epub 2011 Nov 19. APMIS. 2012. PMID: 22515291
-
Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.Pol J Pathol. 2017;68(1):1-10. doi: 10.5114/pjp.2017.67610. Pol J Pathol. 2017. PMID: 28547974
-
Immunohistochemical diagnosis of papillary thyroid carcinoma.Mod Pathol. 2001 Apr;14(4):338-42. doi: 10.1038/modpathol.3880312. Mod Pathol. 2001. PMID: 11301350
-
Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.Diagn Pathol. 2015 Oct 26;10:196. doi: 10.1186/s13000-015-0428-4. Diagn Pathol. 2015. PMID: 26503236 Free PMC article.
-
Papillary thyroid carcinoma variants.Head Neck Pathol. 2011 Mar;5(1):51-6. doi: 10.1007/s12105-010-0236-9. Epub 2011 Jan 8. Head Neck Pathol. 2011. PMID: 21221869 Free PMC article. Review.
Cited by
-
HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.World J Surg Oncol. 2021 May 8;19(1):143. doi: 10.1186/s12957-021-02258-7. World J Surg Oncol. 2021. PMID: 33964951 Free PMC article.
-
The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma.Cureus. 2021 Dec 10;13(12):e20339. doi: 10.7759/cureus.20339. eCollection 2021 Dec. Cureus. 2021. PMID: 34934597 Free PMC article.
-
Diagnostic utility of galectin-3 in thyroid cancer.Am J Pathol. 2010 May;176(5):2067-81. doi: 10.2353/ajpath.2010.090353. Epub 2010 Apr 2. Am J Pathol. 2010. PMID: 20363921 Free PMC article. Review.
-
A Machine Learning-Based Model for Preoperative Assessment and Malignancy Prediction in Patients with Atypia of Undetermined Significance Thyroid Nodules.J Clin Med. 2024 Dec 19;13(24):7769. doi: 10.3390/jcm13247769. J Clin Med. 2024. PMID: 39768693 Free PMC article.
-
Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.Diagn Pathol. 2010 Jan 26;5:9. doi: 10.1186/1746-1596-5-9. Diagn Pathol. 2010. PMID: 20181018 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials